histamine h2 antagonists

Summary

Summary: Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.

Top Publications

  1. pmc Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK
    L A Garcia Rodriguez
    Department of Surgery, P9 03, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
    Gut 55:1538-44. 2006
  2. pmc Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies
    Sandra Dial
    Department of Critical Care, Montreal Chest Institute, QC
    CMAJ 171:33-8. 2004
  3. ncbi Long-term proton pump inhibitor therapy and risk of hip fracture
    Yu Xiao Yang
    Division of Gastroenterology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    JAMA 296:2947-53. 2006
  4. ncbi Systematic review of the risk of enteric infection in patients taking acid suppression
    Jennifer Leonard
    Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada
    Am J Gastroenterol 102:2047-56; quiz 2057. 2007
  5. ncbi Cimetidine enhances immune response of HBV DNA vaccination via impairment of the regulatory function of regulatory T cells
    Junpeng Wang
    State Key Laboratories of Agro biotechnology, College of Biological Science, China Agricultural University, Beijing 100094, China
    Biochem Biophys Res Commun 372:491-6. 2008
  6. pmc Histaminergic signaling in the central nervous system of Daphnia and a role for it in the control of phototactic behavior
    Matthew D McCoole
    Department of Toxicology, College of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209, USA
    J Exp Biol 214:1773-82. 2011
  7. ncbi Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors
    Suresh Jayatilaka
    Division of Gastroenterology, School of Graduate Medical Education, Seton Hall University, South Orange, NY, USA
    Ann Clin Lab Sci 37:241-7. 2007
  8. doi Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure
    Vanessa Stevens
    Center For Health Outcomes, Pharmacoinformatics, and Epidemiology, SUNY Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA
    Pharmacoepidemiol Drug Saf 20:1035-42. 2011
  9. doi Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis
    Chun Shing Kwok
    Norwich Medical School, University of East Anglia, Norwich, UK
    Am J Gastroenterol 107:1011-9. 2012
  10. ncbi Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study)
    Gerhard Treiber
    Department of Gastroenterology Hepatology, University Hospital of Magdeburg, Leipziger Str 44, D 39120 Magdeburg, Germany
    Arch Intern Med 162:153-60. 2002

Detail Information

Publications207 found, 100 shown here

  1. pmc Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK
    L A Garcia Rodriguez
    Department of Surgery, P9 03, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
    Gut 55:1538-44. 2006
    ..Gastric acid suppressing drugs (that is, histamine(2) receptor antagonists and proton pump inhibitors) could affect the risk of oesophageal or gastric adenocarcinoma but few studies are available...
  2. pmc Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies
    Sandra Dial
    Department of Critical Care, Montreal Chest Institute, QC
    CMAJ 171:33-8. 2004
    ..Reduced gastric acidity has been suggested as a risk factor, and we hypothesized that proton pump inhibitors, because of their potency, may be an independent risk factor for this problem...
  3. ncbi Long-term proton pump inhibitor therapy and risk of hip fracture
    Yu Xiao Yang
    Division of Gastroenterology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    JAMA 296:2947-53. 2006
    ..Proton pump inhibitors (PPIs) may interfere with calcium absorption through induction of hypochlorhydria but they also may reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps...
  4. ncbi Systematic review of the risk of enteric infection in patients taking acid suppression
    Jennifer Leonard
    Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada
    Am J Gastroenterol 102:2047-56; quiz 2057. 2007
    ..There have been concerns raised about the possible association of PPIs with enteric infections...
  5. ncbi Cimetidine enhances immune response of HBV DNA vaccination via impairment of the regulatory function of regulatory T cells
    Junpeng Wang
    State Key Laboratories of Agro biotechnology, College of Biological Science, China Agricultural University, Beijing 100094, China
    Biochem Biophys Res Commun 372:491-6. 2008
    ..Collectively these findings suggest that CIM enhances the immune responses of HBV DNA vaccine through the stimulation of pro-inflammatory and inhibition of anti-inflammatory cytokine expression patterns...
  6. pmc Histaminergic signaling in the central nervous system of Daphnia and a role for it in the control of phototactic behavior
    Matthew D McCoole
    Department of Toxicology, College of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209, USA
    J Exp Biol 214:1773-82. 2011
    ..Taken collectively, our results show that an extensive histaminergic system is present in Daphnia species, including the visual system, and that this amine is involved in the control of phototaxis in these animals...
  7. ncbi Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors
    Suresh Jayatilaka
    Division of Gastroenterology, School of Graduate Medical Education, Seton Hall University, South Orange, NY, USA
    Ann Clin Lab Sci 37:241-7. 2007
    ..73, 95%CI: 0.26 to 2.06; p = 0.5520). These data suggest that the widespread prescription of PPI for stress ulcer prophylaxis in acute care facilities may contribute to the increased incidence of CDAD...
  8. doi Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure
    Vanessa Stevens
    Center For Health Outcomes, Pharmacoinformatics, and Epidemiology, SUNY Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA
    Pharmacoepidemiol Drug Saf 20:1035-42. 2011
    ....
  9. doi Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis
    Chun Shing Kwok
    Norwich Medical School, University of East Anglia, Norwich, UK
    Am J Gastroenterol 107:1011-9. 2012
    ..We aimed to perform a systematic review of incident and recurrent CDI in PPI users, and to evaluate the relative impact of concurrent antibiotic use, or switching acid suppression to histamine-2-receptor antagonists (H2RAs)...
  10. ncbi Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study)
    Gerhard Treiber
    Department of Gastroenterology Hepatology, University Hospital of Magdeburg, Leipziger Str 44, D 39120 Magdeburg, Germany
    Arch Intern Med 162:153-60. 2002
    ..Short-term therapies for eradicating Helicobacter pylori in selected patients might offer advantages in terms of costs, compliance, and adverse effects in contrast to standard 1-week triple therapy...
  11. doi Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages
    Eu Jin Cho
    Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 130 701, Republic of Korea
    J Cell Biochem 112:3648-59. 2011
    ..Taken together, these results indicate that the anti-inflammatory properties of roxatidine in LPS-treated RAW 264.7 macrophages are mediated by the inhibition of NF-κB transcriptional activity and the p38 MAP kinase pathway...
  12. pmc Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness
    Stephen Brett
    Department of Anaesthetics and Intensive Care, Hammersmith Hospital, London, UK
    Crit Care 9:45-50. 2005
    ..This review seeks to present the pharmacological evidence that may inform decision-making about the prescription of drugs for prophylaxis of SRMD...
  13. ncbi An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions
    M Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Cancer Res Clin Oncol 125:427-9. 1999
    ....
  14. ncbi Cimetidine-induced vascular cell apoptosis impairs testicular microvasculature in adult rats
    Flávia L Beltrame
    Department of Morphology and Genetics, Federal University of Sao Paulo UNIFESP, Sao Paulo SP, Brazil
    Histol Histopathol 27:1343-51. 2012
    ..A possible antagonist effect of cimetidine on the H₂ receptors and/or androgen receptors in the vascular cells may be responsible for the impairment of the testicular microvasculature...
  15. ncbi Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study
    Rajinder Parshad
    Department of Surgery, All India Institute of Medical Sciences, New Delhi
    Acta Oncol 41:362-5. 2002
    ..01). This study suggests that famotidine enhances tumor infiltrating lymphocytes in breast cancer and might have potential as an immunomodulator. A larger confirmatory study is suggested...
  16. pmc Cimetidine inhibits salivary gland tumor cell adhesion to neural cells and induces apoptosis by blocking NCAM expression
    Masakatsu Fukuda
    Second Division of Oral and Maxillofacial Surgery, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, 1 1 Keyakidai, Sakado, Saitama 350 0283, Japan
    BMC Cancer 8:376. 2008
    ..We further demonstrated that cimetidine inhibited NCAM expression and induced apoptosis in HSG cells. Here, we investigated the effects of cimetidine on growth and perineural/neural invasion of salivary gland tumor cells...
  17. ncbi Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study
    Douglas J Robertson
    VA Medical Center, White River Junction, VT 05009, USA
    Gastroenterology 133:755-60. 2007
    ....
  18. ncbi Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture
    P Vestergaard
    The Osteoporosis Clinic, Aarhus Amtssygehus, Aarhus University Hospital, Tage Hansens Gade 2, DK 8000, Aarhus C, Denmark
    Calcif Tissue Int 79:76-83. 2006
    ..In all cases, the changes in risk estimates were small and the clinical significance was limited...
  19. ncbi A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel
    Janice S Kwon
    Division of Gynecologic Oncology, University of Toronto, Toronto, Ontario, M5S 1A1, Canada
    Gynecol Oncol 84:420-5. 2002
    ....
  20. ncbi A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions
    N Yoshida
    First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan
    Aliment Pharmacol Ther 14:74-81. 2000
    ..Neutrophil-endothelial cell interactions mediated by adhesion molecules may be involved in gastric mucosal inflammation associated with Helicobacter pylori or nonsteroidal anti-inflammatory drugs...
  21. ncbi Gastro-oesophageal reflux disease
    Paul Moayyedi
    Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre, Hamilton, ON, Canada
    Lancet 367:2086-100. 2006
    ..The role of endoscopic therapy is uncertain. Anti-reflux surgery is probably as effective as PPI therapy although there is a low operative mortality and morbidity...
  22. ncbi A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults
    Robert J Valuck
    School of Pharmacy, University of Colorado Health Sciences Center, 4200 E 9th Ave, C 238, Denver, CO 80262, USA
    J Clin Epidemiol 57:422-8. 2004
    ..The purpose of this study was to examine the possible association between use of prescription histamine H-2 receptor antagonists (H2RA) or proton pump inhibitors (PPI) and vitamin B(12) deficiency in older adults...
  23. pmc Histamine inhibits the production of interleukin-12 through interaction with H2 receptors
    T C van der Pouw Kraan
    CLB, Sanquin Blood Supply Foundation, Department of Auto Immune Diseases, Laboratory for Experimental and Clinical Immunology, Academic Medical Centre, University of Amsterdam, 1066CX Amsterdam, The Netherlands
    J Clin Invest 102:1866-73. 1998
    ..The observation that histamine strongly reduces the production of the Th1-inducing cytokine IL-12 implies a positive feedback mechanism for the development of Th2 responses in atopic patients...
  24. pmc Acid-suppressive medications and risk of bone loss and fracture in older adults
    Elaine W Yu
    Endocrine Division, Massachusetts General Hospital, Thier 1101, 50 Blossom Street, Boston, MA 02114, USA
    Calcif Tissue Int 83:251-9. 2008
    ..The use of PPIs in older women, and perhaps older men with low calcium intake, may be associated with a modestly increased risk of nonspine fracture...
  25. ncbi [Effect of maintenance therapy by H2RA on the recurrence of gastric and duodenal ulcer and on the occurrence of reflux esophagitis, gastric erosions, and duodenal erosions after H. pylori eradication]
    Shingo Maeyama
    Department of Gastroenterology, Osaka Rosai Hospital
    Nihon Rinsho 63:512-5. 2005
  26. ncbi Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors
    I J Elenkov
    Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20892, USA
    J Immunol 161:2586-93. 1998
    ....
  27. ncbi Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine
    Tomohiko Shimatani
    Department of General Medicine, Hiroshima University Hospital, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8551, Japan
    Dig Dis Sci 51:114-20. 2006
    ..We concluded that lafutidine increases plasma concentrations of CGRP and somatostatin in humans, which may result in inhibition of postprandial acid secretion and gastroprotective activity...
  28. doi Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates
    F De Vries
    Utrecht Institute for Pharmaceutical Sciences, Universiteit Utrecht, Utrecht, The Netherlands
    Osteoporos Int 20:1989-98. 2009
    ..Positive associations were observed for any hip and vertebral fracture. The effect size was modest; however, the significance lies in the widespread prescribing of acid suppressants...
  29. ncbi Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication
    D Y Graham
    Department of Medicine, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX 77030, USA
    Aliment Pharmacol Ther 17:1229-36. 2003
    ..To compare H2-receptor antagonists and proton pump inhibitors as adjuvants to triple therapy for Helicobacter pylori eradication...
  30. ncbi Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients
    Eva Untersmayr
    Center of Physiology and Pathophysiology, Medical University Vienna, Vienna, Austria
    FASEB J 19:656-8. 2005
    ..In line with our previous animal experiments, our data strongly suggest that anti-ulcer treatment primes the development of IgE toward dietary compounds in long-term acid-suppressed patients...
  31. pmc Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells
    S Matsumoto
    Department of Surgery, Second Teaching Hospital, School of Medicine, Fujita Health University, 3 6 10 Otohbashi, Nakagawa Ku, Nagoya 454 8509, Japan
    Br J Cancer 86:161-7. 2002
    ..0% and that of control group was 85.7% (P=n.s.)). These results clearly indicate that cimetidine treatment dramatically improved survival in colorectal cancer patients with tumour cells expressing high levels of sL(x) and sL(a)...
  32. ncbi Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment
    Y Ashida
    Skin Biology Research Laboratories, Life Science Research Center, Shiseido Research Center, 2 12 1 Fukuura, Kanazawa Ku, Yokohama 236 8643, Japan
    J Invest Dermatol 116:261-5. 2001
    ..In conclusion, both the histamine H1 and H2 receptors in the epidermis are involved in skin barrier function and the cutaneous condition of epidermal hyperplasia...
  33. pmc Gastro-protective action of lafutidine mediated by capsaicin-sensitive afferent neurons without interaction with TRPV1 and involvement of endogenous prostaglandins
    Kazuhiro Fukushima
    Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Yamashina, Kyoto 607, Japan
    World J Gastroenterol 12:3031-7. 2006
    ..We compared the effect between lafutidine and capsaicin, with respect to the interaction with endogenous prostaglandins (PG), nitric oxide (NO) and the afferent neurons, including transient receptor potential vanilloid subtype 1 (TRPV1)...
  34. ncbi Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review)
    Florence Lefranc
    Department of Neurosurgery, Erasmus University Hospital, Brussels, Belgium
    Int J Oncol 28:1021-30. 2006
    ....
  35. ncbi Does cimetidine improve prospects for cancer patients?. A reappraisal of the evidence to date
    C P Siegers
    Department of Experimental and Clinical Pharmacology and Toxicology, Medical University of Lubeck, Germany
    Digestion 60:415-21. 1999
    ..Since then, several studies have appeared which suggest an anticancer activity for cimetidine, although few attempts have been made to corroborate their findings in large, placebo-controlled, double-blind studies...
  36. ncbi Effect of lafutidine, a histamine H2-receptor antagonist, on gastric mucosal blood flow and duodenal HCO3- secretion in rats: relation to capsaicin-sensitive afferent neurons
    Hiroshi Mimaki
    Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto 607 8414, Japan
    Dig Dis Sci 47:2696-703. 2002
    ..The luminal H+ itself is not a ligand for the RT-sensitive site of VR1 but plays a modulator role in the CSN-mediated physiological responses...
  37. ncbi Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey
    William D Chey
    University of Michigan Health System, Ann Arbor, Michigan 49109 0362, USA
    Am J Gastroenterol 100:1237-42. 2005
    ..Gastroesophageal reflux disease (GERD) is frequently managed by primary-care physicians (PCPs) although little is known about their current practices and management patterns...
  38. ncbi Gastroprotective mechanism of lafutidine, a novel anti-ulcer drug with histamine H2-receptor antagonistic activity
    S Onodera
    Pharmaceuticals Research Laboratories, Fujirebio Inc, Tokyo, Japan
    Arzneimittelforschung 49:519-26. 1999
    ....
  39. ncbi Inhibition of neutrophil activation by lafutidine, an H2-receptor antagonist, through enhancement of sensory neuron activation contributes to the reduction of stress-induced gastric mucosal injury in rats
    Naoaki Harada
    Department of Biodefense Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Dig Dis Sci 52:469-77. 2007
    ..These observations suggest that lafutidine might reduce WIR-induced gastric mucosal injury not only by inhibiting acid secretion but also by inhibiting neutrophil activation through enhancement of sensory neuron activation...
  40. ncbi Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa
    Takafumi Ichikawa
    Department of Biochemistry, Kitasato University School of Medicine, Sagamihara, Japan
    J Gastroenterol Hepatol 22:1800-5. 2007
    ..Previous human studies have not assessed its gastroprotective effects. The purpose of the present study was to determine the effects of lafutidine on the human gastric mucus layer using both histological and biochemical methods...
  41. pmc Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth
    J A Lawson
    UNSW Department of Surgery, The St George Hospital, Kogarah Sydney, Australia
    Br J Cancer 73:872-6. 1996
    ..LIM2412, another colonic cancer cell line, was significantly stimulated by both cimetidine and ranitidine in vivo. Ranitidine had no effect on in vitro cell proliferation...
  42. ncbi Protective effect of lafutidine, a novel histamine H2-receptor antagonist, on dextran sulfate sodium-induced colonic inflammation through capsaicin-sensitive afferent neurons in rats
    Mitsuaki Okayama
    Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto 607 8414, Japan
    Dig Dis Sci 49:1696-704. 2004
    ..This action might be attributable at least partly to the enhancement of colonic mucus secretion...
  43. ncbi Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor
    J Mark Ruscin
    Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, 4200 E Ninth Avenue, Denver, CO 80262 0001, USA
    Ann Pharmacother 36:812-6. 2002
    ..To report a case of vitamin B(12) deficiency associated with long-term use (approximately 4 1/2 y) of histamine(2) (H(2))-receptor antagonists and a proton-pump inhibitor (PPI) in a patient with gastroesophageal reflux...
  44. ncbi Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial
    Ilona Kantorova
    Traumatological Hospital Brno, Research Center for Traumatology and Surgery, Czech Republic
    Hepatogastroenterology 51:757-61. 2004
    ..There are conflicting data on the efficacy and complication rates of various prophylactic regimens...
  45. pmc Proton pump inhibitors and risk of gastric cancer: a population-based cohort study
    A H Poulsen
    Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Br J Cancer 100:1503-7. 2009
    ....
  46. pmc Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group
    M J Langman
    Department of Medicine, CRC Institute for Cancer Studies, Clinical Research Block, The Medical School, Edgbaston, Birmingham, UK
    Br J Cancer 81:1356-62. 1999
    ..Cimetidine at a dose of 400 mg or 800 mg twice a day does not have a significant influence on the survival of patients with gastric cancer compared to placebo...
  47. ncbi H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?
    Emily E Wade
    Department of Pharmacy, University of Pittsburgh Medical Center, 304 Scaife Hall, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Intensive Care Med 28:459-65. 2002
    ..We evaluate the literature to better define thrombocytopenia related to H(2) antagonist administration and discuss mechanism, potential as a risk factor and case reports describing the severity and duration of thrombocytopenia...
  48. ncbi Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study
    J H Van Zyl
    Department of Medicine and Gastroenterology at University of The Orange Free State, Bloemfontein, South Africa
    Eur J Gastroenterol Hepatol 12:197-202. 2000
    ....
  49. ncbi Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding
    Rebecca M Huggins
    Department of Pharmacy, Duke University Medical Center, Durham, NC 27710, USA
    Ann Pharmacother 37:433-7. 2003
    ..To evaluate the evidence supporting the use of intravenous proton-pump inhibitors in the treatment of gastrointestinal (GI) hemorrhage in comparison with histamine(2) (H(2))-receptor antagonists...
  50. ncbi Current guidelines on stress ulcer prophylaxis
    M Tryba
    Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Bergmannsheil, Bochum, Germany
    Drugs 54:581-96. 1997
    ..The clinical relevance of nosocomial pneumonia due to gastric bacterial overgrowth has decreased during the past decade due to several changes in the management of critically ill patients...
  51. ncbi Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group
    J B Jansen
    Department of Gastroenterology, Academic Hospital Nijmegen St Radboud, Nijmegen, The Netherlands
    Aliment Pharmacol Ther 13:1611-20. 1999
    ..In an attempt to compensate for the lower efficacy, H2-receptor antagonists are now increasingly being used at a higher dose...
  52. ncbi [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002]
    György Miklós Buzás
    Ferencvárosi Egészségügyi Szolgálat, Gasztroenterológia
    Orv Hetil 145:2035-41. 2004
    ..Meta-analyses evaluated several aspects of Helicobacter pylori eradication based on the randomised controlled trials...
  53. ncbi In vitro availability studies of enoxacin in presence of H2 receptor antagonists
    M Saeed Arayne
    Department of Chemistry, University of Karachi Karachi 75270, Pakistan
    Pak J Pharm Sci 20:235-43. 2007
    ....
  54. ncbi Alteration of intracellular histamine H2 receptor cycling precedes antagonist-induced upregulation
    Satoshi Osawa
    First Dept of Medicine, Hamamatsu Univ School of Medicine, 1 20 1 Handayama, Hamamatsu 431 3192, Japan
    Am J Physiol Gastrointest Liver Physiol 289:G880-9. 2005
    ..These findings suggested that upon exposure to an antagonist (inverse agonist), the equilibrium between receptor endocytosis and recycling is altered before H2R upregulation, probably via suppressing H2R degradation...
  55. ncbi Development of an HPLC method for the determination of ranitidine and cimetidine in human plasma following SPE
    Dragica Zendelovska
    Institute of Preclinical and Clinical Pharmacology and Toxicology, Sts Cyril and Methodius University, Medical Faculty, 50 Divizija bb, 1000 Skopje, Macedonia
    J Pharm Biomed Anal 33:165-73. 2003
    ..8 and 14% acetonitrile. The recovery, selectivity, linearity, precision and accuracy of the method were evaluated from spiked human plasma. The method has been implemented to monitor ranitidine levels in clinical samples...
  56. ncbi Nasal pain disrupting sleep as a presenting symptom of extraesophageal acid reflux in children
    Seckin Ulualp
    Department of Otolaryngology, University at Buffalo, School of Medicine and Biomedical Sciences and the Women and Children s Hospital, 219 Bryant Street, Buffalo, NY 14209, USA
    Int J Pediatr Otorhinolaryngol 69:1555-7. 2005
    ..This is the first report documenting nasal pain resolved with acid suppressive therapy in a child with EERD. The incidence and pathogenesis of EERD induced nasal symptoms in children merits further investigation...
  57. ncbi [Pharmacotherapy in complex treatment of ulcerous stenosis]
    N V Rukhliada
    Vestn Khir Im I I Grek 162:97-100. 2003
    ..The results obtained show that it is necessary to determine the indications to operations in patients with ulcerous stenosis after complex conservative therapy and the reassessment of the degree of evacuatory disorders...
  58. ncbi Spermicidal efficacy of H2-receptor antagonists and potentiation with 2', 4'-dichlorobenzamil hydrochloride: role of intrasperm Ca2+
    A Gupta
    Department of Pharmaceutical Sciences and Drug Research, Punjabi University, 147 002, Patiala, India
    Contraception 68:61-4. 2003
    ..These results suggest that elevation of intrasperm Ca(2+) by H(2)-receptor antagonists plays a key role in influencing sperm viability...
  59. ncbi The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review
    Manishi Prasad
    MEDTAP International, Bethesda, MD 20814, USA
    Pharmacoeconomics 21:769-90. 2003
    ..Although there is evidence that treatment for GORD does improve symptoms and HR-QOL outcomes, further research is needed to more completely understand the value of medical therapy for GORD...
  60. ncbi Oesophageal acid-peptic strictures in the histamine H2 receptor antagonist and proton pump inhibitor era
    A K Nayyar
    Rotherham General Hospitals NHS Trust, Rotherham, South Yorkshire S60 2UD, UK
    Dig Liver Dis 35:143-50. 2003
    ..We present a survey on the incidence, demography and natural history (re-dilatation rates) of patients with oesophageal acid-peptic stricture seen between 1977 and 1995...
  61. ncbi The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy
    Kazuyoshi Hirota
    Department of Anesthesiology, University of Hirosaki School of Medicine, Hirosaki 036 8563, Japan
    Anesth Analg 101:1038-41, table of contents. 2005
    ..05) were at risk. These data suggest that in patients receiving H2-antagonist therapy for longer than 4 wk, prophylaxis for acid aspiration pneumonia should include preanesthetic PPI medication...
  62. ncbi [Helicobacter pylori eradication. Triple or quadruple therapy?, Long or short treatment?]
    X Calvet
    Unitat de Malalties Digestives Hospital de Sabadell Institut Universitari Parc Taulí UAB Sabadell Barcelona España
    Gastroenterol Hepatol 26:325-9. 2003
  63. ncbi Gastroesophageal reflux and histamine2 antagonists
    Susan Givens Bell
    NICU, All Children s Hospital, St Petersburg, Florida, USA
    Neonatal Netw 22:53-7. 2003
  64. ncbi Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer
    Paul R Walker
    Division of Medical Oncology and Hematology, Medical University of Ohio at Toledo, Ruppert Center, 3120 Glendale Avenue, Toledo, OH 43614, USA
    Cancer Biother Radiopharm 20:487-90. 2005
    ..In this study of CIV IL-2 and antihistamines, this combination appears to be active in metastatic kidney cancer. There appears to be no negative effect of antihistamine on the CIV IL-2 response rate in this disease...
  65. ncbi Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study
    D Armstrong
    Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada
    Aliment Pharmacol Ther 21:1189-202. 2005
    ..There are few data on empiric, stepped therapy for heartburn relief or subsequent relapse in primary care...
  66. ncbi Gastroesophageal reflux disease: current treatment approaches
    Wendy Biddle
    Director 11:155-9. 2003
  67. ncbi Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs
    Alexa M E Bersenas
    Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada
    Am J Vet Res 66:425-31. 2005
    ..To identify the normal gastric acid secretion profile in dogs and determine the degree of gastric acid suppression associated with 4 gastric acid suppressants...
  68. ncbi Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children
    Roberto Berni Canani
    Department of Pediatrics, University Federico II of Naples, Naples, Italy
    Pediatrics 117:e817-20. 2006
    ..To test the hypothesis that GA suppression could be associated with an increased risk of acute gastroenteritis and pneumonia in children treated with GA inhibitors, we conducted a multicenter, prospective study...
  69. doi Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer
    Robert W Mathes
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 17:67-72. 2008
    ..The few previous studies evaluating this association have been null but have been limited by small sample sizes, and none have evaluated risk by either histologic type or estrogen receptor/progesterone receptor status...
  70. ncbi Effects of cimetidine-like drugs on recombinant GABAA receptors
    Keri E Cannon
    Center for Neuropharmacology and Neuroscience, Albany Medical College MC 136, 47 New Scotland Ave, Albany, NY 12206, USA
    Life Sci 75:2551-8. 2004
    ....
  71. ncbi The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach
    Kun Wang
    Division of Gastroenterology, Department of Medicine, Cardinal Tien Hospital and School of Medicine Fu Jen Catholic University, Taipei, Taiwan, ROC
    Hepatogastroenterology 51:1540-3. 2004
    ..The purpose of this study was to investigate the microbial condition of the stomach in patients who received H2-receptor antagonist or proton pump inhibitor...
  72. ncbi [PPI: new strategies for GERD]
    Etsuo Hoshino
    Department of Internal Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research
    Nihon Rinsho 62:1570-6. 2004
    ..A small number of GERD patients resistant to PPI therapy may be due to nocturnal acid breakthrough (NAB) or rapid metabolism of PPI (extensive metabolizer for CYP2C19)...
  73. ncbi Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3
    Yoshinori Nagata
    Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7 3 1, Hongo, Bunkyo ku, Tokyo 113 0033, Japan
    Drug Metab Dispos 32:1040-7. 2004
    ..These results suggest that rOat3 is the most likely candidate transporter involved in regulating the CSF concentration of H(2)-receptor antagonists at the CP...
  74. ncbi Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: application to the analysis of ranitidine and its metabolites in human volunteers
    Diane A I Ashiru
    Department of Pharmaceutics, The School of Pharmacy, University of London, 29 39 Brunswick Square, London WC1N 1AX, UK
    J Chromatogr B Analyt Technol Biomed Life Sci 860:235-40. 2007
    ..The assay was successfully applied to a human volunteer study using ranitidine as the model compound...
  75. ncbi [Modern attitude towards management of laryngopharyngeal form of gastroesophageal reflux disease. Lithuanian clinical practice guidelines for adults]
    Nora Siupsinskiene
    Department of Otorhinolaryngology, Kaunas University of Medicine, Kaunas, Lithuania
    Medicina (Kaunas) 43:832-9. 2007
    ..Combined therapy for nonresponders is described. Algorithm for stopping the medication is recommended. These recommendations may provide an efficient and economical approach to the management of this problem...
  76. ncbi Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates
    K I Umehara
    Drug Metabolism Research Laboratories, Drug Discovery Research, Azusawa, Tokyo, Japan
    Xenobiotica 37:618-34. 2007
    ..The acquisition of information on OCT/Oct mediated-transport and/or inhibition such as that presented in this report is very useful for further understanding of certain aspects of uptake, distribution, and excretion for drug candidates...
  77. ncbi [Bronchial asthma and gastroesophageal reflux disease: are they interrelated by chance?]
    N R Paleev
    Klin Med (Mosk) 83:9-14. 2005
  78. ncbi [Treatment of gastroesophageal reflux disease]
    Laszlo Herszenyi
    Semmelweis Egyetem, Általános Orvostudományi Kar, II Belgyógyászati Klinika, Budapest
    Orv Hetil 144:2571-3. 2003
  79. ncbi Is an intravenous histamine H2 receptor antagonist superior to an intravenous proton pump inhibitor in acid suppression?
    Yoshikazu Kinoshita
    J Gastroenterol 39:92-3. 2004
  80. ncbi Omeprazole is more effective than a histamine H2-receptor blocker for maintaining a persistent elevation of gastric pH after colon resection for cancer
    Tzu Chi Hsu
    Colon and Rectal Surgery, Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan
    Am J Surg 187:20-3. 2004
    ..An assessment was made of the change and the effect of a histamine H(2)-receptor blocker (H(2)-blocker) or omeprazole on gastric pH after surgery...
  81. ncbi A new sensitive flow-injection chemiluminescence method for the determination of H(2)-receptor antagonists
    Yu Hai Tang
    Institute of Analytical Chemistry, Xi an Jiaotong University, Xi an 710061, People s Republic of China
    Luminescence 22:343-8. 2007
    ..56 x 10(-10) g/mL for CIMT, 8.69 x 10(-10) g/mL for RANT hydrochloride and 2.35 x 10(-9) g/mL for FAMT (S:N = 3). This method has been successfully implemented for the analysis of H(2)-receptor antagonists in pharmaceuticals...
  82. ncbi Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level
    T Ohsawa
    Chidoribashi Hospital Pharmacy, Department of Pharmacokinetics, Faculty of Pharmaceutical Science, Kyushu University, Fukuoka, Japan
    Int J Clin Pharmacol Res 22:29-35. 2002
    ..Gastrin level was highest in patients administered famotidine and lowest among those administered cimetidine. The pattern of gastrin change in patients administered ranitidine was intermediate between famotidine and cimetidine...
  83. ncbi [Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer]
    Iu B Belousov
    Ter Arkh 79:58-66. 2007
  84. ncbi In vitro interactions of captopril with H2-receptor antagonists
    Najma Sultana
    Department of Pharmaceutical Chemistry, Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy, University of Karachi, Karachi 75270, Pakistan
    Pak J Pharm Sci 20:132-9. 2007
    ..As a result, the availability of captopril was affected by the concurrent administration of H2-receptor antagonists. Accordingly coadministration of both the drugs should be avoided...
  85. ncbi Decrease of intragastric acidity in healthy subjects dosed with ranitidine 75 mg, cimetidine 200 mg, or placebo
    Mark I Hamilton
    Centre for Gastroenterology, Royal Free and University College Medical School, London, UK
    Dig Dis Sci 47:54-7. 2002
    ..043). The inhibitory effect of ranitidine, 75 mg, on intragastric acidity can be detected from 0-15 hr after an oral dose. Cimetidine 200 mg has little inhibitory effect beyond 10 hr...
  86. ncbi Fosinopril H(2)-receptor antagonists interaction studies by derivative spectroscopy
    Najma Sultana
    Research Institute of Pharmaceutical Sciences, University of Karachi, Karachi 75270, Pakistan
    Pak J Pharm Sci 20:19-25. 2007
    ....
  87. ncbi [Safety of proton pump inhibitors]
    Juan V Esplugues
    Departamento de Farmacologia, Facultat de Medicina i Odontologia, Universitat de Valencia, Valencia, Espana
    Med Clin (Barc) 127:790-5. 2006
    ..After two decades of use, PPIs have proved to be very effective and safe drugs...
  88. ncbi Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies
    C W Howden
    Northwestern University Medical School, Chicago, Illinois, USA
    Am J Gastroenterol 96:1704-10. 2001
    ..CONCLUSION: Proton pump inhibitor treatment provides more consistent heartburn relief than an H2-receptor antagonist, or "step-up" or "step-down" therapy...
  89. ncbi Effects of histamine 2 receptor antagonists on endothelial-neutrophil adhesion and surface expression of endothelial adhesion molecules induced by high glucose levels
    Yoshiyuki Takeuchi
    Department of Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    J Diabetes Complications 21:50-5. 2007
    ..These data suggest that cimetidine acts directly on endothelial cells to inhibit high-glucose-induced expression of adhesion molecules and neutrophil adhesion mediated by increasing endothelial NO production, but not by inhibiting PKC...
  90. ncbi [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis]
    Hyun Yong Jeong
    Department of Internal Medicine, Chungnam National University College of Medicine, Chungnam, Korea
    Korean J Gastroenterol 47:15-21. 2006
    ..This study was done to evaluate the efficacy of rabeprazole (proton-pump-inhibitor) and ranitidine (H(2)-receptor antagonist) in the symptom relief and treatment of erosive esophagitis diagnosed by endoscopy...
  91. ncbi In vitro availability of metformin in presence of h(2) receptor antagonists
    Najma Sultana
    Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy, University of Karachi, Karachi 75270, Pakistan
    Pak J Pharm Sci 19:28-34. 2006
    ..On the other hand, increase in metformin concentration may result in hypoglycemic effects...
  92. ncbi [Activity of malondialdehyde in rat plasma after H2 histamine receptor blockade]
    B Burak

    Ann Univ Mariae Curie Sklodowska Med 54:63-7. 1999
    ..The level of the MDA was determined from the plasma and compared to the 1 mg of the blood protein. None of administered H2 blockers changed the malondialdehyde level in serum of the experimental rats...
  93. ncbi [The effect of H2 receptor blockers on renal function. An attempt to accurately measure glomerular filtration]
    Waldemar Motyl
    Z Oddziału Wewnetrznego Szpitala Powiatowego w Drawsku Pomorskim, ul Bolesława Chrobrego 4, 78 500 Drawsko Pomorskie
    Ann Acad Med Stetin 50:97-105. 2004
    ..The present findings suggest that the full dose of cimetidine is capable of inhibiting tubular transport of creatinine and thus may improve the accuracy of creatinine clearance measurements for the study of renal function...
  94. pmc pH, healing rate, and symptom relief in patients with GERD
    J Q Huang
    Department of Medicine, McMaster University Medical Center, Hamilton, Ontario, Canada
    Yale J Biol Med 72:181-94. 1999
    ....
  95. pmc Histamine signaling through the H(2) receptor in the Peyer's patch is important for controlling Yersinia enterocolitica infection
    Scott A Handley
    Department of Molecular Microbiology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Proc Natl Acad Sci U S A 103:9268-73. 2006
    ..In this study, we provide evidence that histamine signaling through the histamine H(2) but not the H(1) receptor is important for controlling Y. enterocolitica infection within the Peyer's patches and mesenteric lymph nodes of mice...
  96. ncbi Drugs for bleeding peptic ulcer
    P Netzer
    Aliment Pharmacol Ther 16:645-6. 2002
  97. ncbi Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough
    William K Fackler
    Center for Swallowing and Esophageal Disorders, Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gastroenterology 122:625-32. 2002
    ..Controversy exists over its efficacy because of H2RA intolerance. No prospective study has addressed this issue...
  98. ncbi Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide
    Hiroki Itoh
    Department of Clinical Pharmacy, Oita Medical University, Hasama machi, Oita 879 5593, Japan
    J Pharm Pharmacol 54:1559-63. 2002
    ..The released CGRP and SP by ranitidine and nizatidine administration may produce a gastroprotective effect, increase mucosal blood flow, and inhibit acid secretion in the gastrointestinal tract...
  99. ncbi Determination of cimetidine, famotidine, and ranitidine hydrochloride in the presence of their sulfoxide derivatives in pure and dosage forms by high-performance thin-layer chromatography and scanning densitometry
    Khadiga M Kelani
    Cairo University, Faculty of Pharmacy, Department of Analytical Chemistry, Egypt
    J AOAC Int 85:1015-20. 2002
    ..The results obtained were analyzed statistically and compared with those obtained by the official methods...
  100. ncbi Spectrophotometric determination of H(2)-receptor antagonists via their oxidation with cerium(IV)
    Ibrahim A Darwish
    Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
    Spectrochim Acta A Mol Biomol Spectrosc 69:33-40. 2008
    ..3-102.6+/-0.57-1.90%) without interference from the common excipients. The results obtained by the proposed method were comparable with those obtained by the official methods...
  101. ncbi Determination of the time of onset of action of ranitidine and famotidine on intra-gastric acidity
    J D Gardner
    Science for Organizations, Inc, Chatham, NJ 07928, USA
    Aliment Pharmacol Ther 16:1317-26. 2002
    ..No standard methods exist for determining the onset of action of gastric antisecretory agents in human subjects...

Research Grants105 found, 100 shown here

  1. GASTRIC ACID SECRETION AND BUFFER CONTENT AFTER EATING
    JOHN FORDTRAN; Fiscal Year: 1980
    ....
  2. CASE-CONTROL SURVEILLANCE OF SERIOUS ILLNESSES AND DRUGS
    Lynn Rosenberg; Fiscal Year: 2003
    ..One focus of CCS analyses will be the relation of the widely used drug classes, statins, histamine H2 antagonists, and selective serotonin uptake inhibitors, to risk of common cancers...
  3. CASE-CONTROL SURVEILLANCE OF SERIOUS ILLNESSES AND DRUGS
    Lynn Rosenberg; Fiscal Year: 2007
    ..One focus of CCS analyses will be the relation of the widely used drug classes, statins, histamine H2 antagonists, and selective serotonin uptake inhibitors, to risk of common cancers...
  4. CASE-CONTROL SURVEILLANCE OF SERIOUS ILLNESSES AND DRUGS
    Lynn Rosenberg; Fiscal Year: 2006
    ..One focus of CCS analyses will be the relation of the widely used drug classes, statins, histamine H2 antagonists, and selective serotonin uptake inhibitors, to risk of common cancers...
  5. CASE-CONTROL SURVEILLANCE OF SERIOUS ILLNESSES AND DRUGS
    Lynn Rosenberg; Fiscal Year: 2004
    ..One focus of CCS analyses will be the relation of the widely used drug classes, statins, histamine H2 antagonists, and selective serotonin uptake inhibitors, to risk of common cancers...
  6. CASE-CONTROL SURVEILLANCE OF SERIOUS ILLNESSES AND DRUGS
    Lynn Rosenberg; Fiscal Year: 2005
    ..One focus of CCS analyses will be the relation of the widely used drug classes, statins, histamine H2 antagonists, and selective serotonin uptake inhibitors, to risk of common cancers...
  7. Alzheimer's Disease Patient Registry (ADPR)
    Eric Larson; Fiscal Year: 2004
    ..The results of these studies will be invaluable to the development and testing of strategies to reduce the risk of AD and related conditions, and to reduce the burden of cognitive decline in the growing population of older persons. ..
  8. Alzheimer's Disease Patient Registry (ADPR)
    Eric Larson; Fiscal Year: 2006
    ..The results of these studies will be invaluable to the development and testing of strategies to reduce the risk of AD and related conditions, and to reduce the burden of cognitive decline in the growing population of older persons. ..
  9. Alzheimer's Disease Patient Registry (ADPR)
    Eric Larson; Fiscal Year: 2005
    ..The results of these studies will be invaluable to the development and testing of strategies to reduce the risk of AD and related conditions, and to reduce the burden of cognitive decline in the growing population of older persons. ..
  10. Alzheimer's Disease Patient Registry (ADPR)
    Eric Larson; Fiscal Year: 2007
    ..The results of these studies will be invaluable to the development and testing of strategies to reduce the risk of AD and related conditions, and to reduce the burden of cognitive decline in the growing population of older persons. ..
  11. NSAIDS and Other Medications in Prostate Cancer Etiology
    Janet Stanford; Fiscal Year: 2004
    ..Results of the study may provide unique insights on the pathogenesis of this complex disease and lead to innovative strategies for prostate cancer prevention. ..
  12. NSAIDS and Other Medications in Prostate Cancer Etiology
    Janet Stanford; Fiscal Year: 2001
    ..Results of the study may provide unique insights on the pathogenesis of this complex disease and lead to innovative strategies for prostate cancer prevention. ..
  13. NSAIDS and Other Medications in Prostate Cancer Etiology
    Janet Stanford; Fiscal Year: 2002
    ..Results of the study may provide unique insights on the pathogenesis of this complex disease and lead to innovative strategies for prostate cancer prevention. ..
  14. NSAIDS and Other Medications in Prostate Cancer Etiology
    Janet Stanford; Fiscal Year: 2003
    ..Results of the study may provide unique insights on the pathogenesis of this complex disease and lead to innovative strategies for prostate cancer prevention. ..
  15. NSAIDS and Other Medications in Prostate Cancer Etiology
    Janet Stanford; Fiscal Year: 2005
    ..Results of the study may provide unique insights on the pathogenesis of this complex disease and lead to innovative strategies for prostate cancer prevention. ..
  16. EPIDEMIOLOGY OF DEMENTIA IN CACHE COUNTY, UTAH
    John Breitner; Fiscal Year: 1999
    ..These exposures will receive emphasis in the incidence phase of the study as a likely preface to randomized primary prevention trials. ..
  17. EPIDEMIOLOGY OF DEMENTIA IN CACHE COUNTY, UTAH
    John Breitner; Fiscal Year: 2001
    ..These exposures will receive emphasis in the incidence phase of the study as a likely preface to randomized primary prevention trials. ..
  18. EPIDEMIOLOGY OF DEMENTIA IN CACHE COUNTY, UTAH
    John Breitner; Fiscal Year: 2000
    ..These exposures will receive emphasis in the incidence phase of the study as a likely preface to randomized primary prevention trials. ..
  19. GASTRIC BIOLOGY OF HELICOBACTER PYLORI
    George Sachs; Fiscal Year: 2006
    ..pylori has evolved to colonize the human stomach. These studies may provide targets to allow eradication of this class 1 carcinogen without the use of general antibiotics. ..
  20. GASTRIC BIOLOGY OF HELICOBACTER PYLORI
    George Sachs; Fiscal Year: 2003
    ..pylori has evolved to colonize the human stomach. These studies may provide targets to allow eradication of this class 1 carcinogen without the use of general antibiotics. ..
  21. GASTRIC BIOLOGY OF HELICOBACTER PYLORI
    George Sachs; Fiscal Year: 2002
    ..Understanding the means of survival and cytotoxicity of this pathogen will enable more rational treatment of peptic ulcer disease. ..
  22. GASTRIC ENTEROCHROMAFFIN-LIKE CELL IN ULCER DISEASE
    George Sachs; Fiscal Year: 2004
    ..Hence this approach will provide additional insights into mechanisms of regulation of gastric secretion and enable illuminated interpretation of the pathophysiology of peptic ulcer disease. ..
  23. The Gastric Biology of Helicobacter Pylori
    George Sachs; Fiscal Year: 2009
    ..A better understanding of effects of acid inhibition on H. pylori may allow improvement or replacement of triple therapy for eradication. ..
  24. GASTRIC ENTEROCHROMAFFIN-LIKE CELL IN ULCER DISEASE
    George Sachs; Fiscal Year: 2005
    ..Hence this approach will provide additional insights into mechanisms of regulation of gastric secretion and enable illuminated interpretation of the pathophysiology of peptic ulcer disease. ..
  25. GASTRIC BIOLOGY OF HELICOBACTER PYLORI
    George Sachs; Fiscal Year: 2004
    ..pylori has evolved to colonize the human stomach. These studies may provide targets to allow eradication of this class 1 carcinogen without the use of general antibiotics. ..
  26. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2004
    ....
  27. GASTRIC ENTEROCHROMAFFIN-LIKE CELL IN ULCER DISEASE
    George Sachs; Fiscal Year: 2002
    ..Hence this approach will provide additional insights into mechanisms of regulation of gastric secretion and enable illuminated interpretation of the pathophysiology of peptic ulcer disease. ..
  28. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2002
    ....
  29. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2009
    ..The results of the proposed research will further improve the agents used for the treatment of acid-related diseases and also our knowledge of the ATPase and cellular events involved in regulation of its activity. ..
  30. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2004
    ....
  31. GASTRIC ENTEROCHROMAFFIN LIKE CELL IN ULCER DISEASE
    George Sachs; Fiscal Year: 1999
    ..These data will allow a novel understanding of the peripheral regulation of gastric acid secretion as well as the exocytotic process in a non- excitable endocrine cell. ..
  32. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2008
    ..The results of the proposed research will further improve the agents used for the treatment of acid-related diseases and also our knowledge of the ATPase and cellular events involved in regulation of its activity. ..
  33. GASTRIC BIOLOGY OF HELICOBACTER PYLORI
    George Sachs; Fiscal Year: 2005
    ..pylori has evolved to colonize the human stomach. These studies may provide targets to allow eradication of this class 1 carcinogen without the use of general antibiotics. ..
  34. GASTRIC BIOLOGY OF HELICOBACTER PYLORI
    George Sachs; Fiscal Year: 2001
    ..Understanding the means of survival and cytotoxicity of this pathogen will enable more rational treatment of peptic ulcer disease. ..
  35. GASTRIC BIOLOGY OF HELICOBACTER PYLORI
    George Sachs; Fiscal Year: 1999
    ..Understanding the means of survival and cytotoxicity of this pathogen will enable more rational treatment of peptic ulcer disease. ..
  36. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2006
    ..The results of the proposed research will further improve the agents used for the treatment of acid-related diseases and also our knowledge of the ATPase and cellular events involved in regulation of its activity. ..
  37. GASTRIC ENTEROCHROMAFFIN-LIKE CELL IN ULCER DISEASE
    George Sachs; Fiscal Year: 1999
    ..Hence this approach will provide additional insights into mechanisms of regulation of gastric secretion and enable illuminated interpretation of the pathophysiology of peptic ulcer disease. ..
  38. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2002
    ....
  39. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2005
    ..The results of the proposed research will further improve the agents used for the treatment of acid-related diseases and also our knowledge of the ATPase and cellular events involved in regulation of its activity. ..
  40. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2002
    ....
  41. The Gastric Biology of Helicobacter Pylori
    George Sachs; Fiscal Year: 2010
    ..A better understanding of effects of acid inhibition on H. pylori may allow improvement or replacement of triple therapy for eradication. ..
  42. NON-OPIOID ANALGESICS DERIVED FROM IMPROGAN
    LINDSAY HOUGH; Fiscal Year: 2006
    ..These experiments will help to discover the mechanism of action of this novel class of agents, and lead to the development of new pharmacotherapies for pain. ..
  43. P450 Epoxygenase Mechanisms of Opioid Analgesia
    LINDSAY HOUGH; Fiscal Year: 2010
    ..This proposal will uncover new biochemical mechanisms for pain relief, and test a new group of chemicals for pain-relieving properties. This research could lead to the development of new, non-addicting pain relievers. ..
  44. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 2008
    ..abstract_text> ..
  45. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  46. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 2008
    ..abstract_text> ..
  47. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 2009
    ..abstract_text> ..
  48. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  49. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 2001
    ....
  50. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 2002
    ....
  51. HISTAMINERGIC MECHANISMS OF ANALGESIA
    LINDSAY HOUGH; Fiscal Year: 1991
    ..These studies will enhance our knowledge of antinociceptive mechanisms, and may lead to the development of novel, clinically useful agents for the relief of pain...
  52. NON-OPIOID ANALGESICS DERIVED FROM IMPROGAN
    LINDSAY HOUGH; Fiscal Year: 2003
    ..These experiments will help to discover the mechanism of action of this novel class of agents, and lead to the development of new pharmacotherapies for pain. ..
  53. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 2003
    ....
  54. NON-OPIOID ANALGESICS DERIVED FROM IMPROGAN
    LINDSAY HOUGH; Fiscal Year: 2004
    ..These experiments will help to discover the mechanism of action of this novel class of agents, and lead to the development of new pharmacotherapies for pain. ..
  55. HISTAMINERGIC MECHANISMS OF ANALGESIA
    LINDSAY HOUGH; Fiscal Year: 1992
    ..These studies will enhance our knowledge of antinociceptive mechanisms, and may lead to the development of novel, clinically useful agents for the relief of pain...
  56. NON-OPIOID ANALGESICS DERIVED FROM IMPROGAN
    LINDSAY HOUGH; Fiscal Year: 2005
    ..These experiments will help to discover the mechanism of action of this novel class of agents, and lead to the development of new pharmacotherapies for pain. ..
  57. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 1999
    ..These studies will clarify the mechanisms by which MOR relieves pain, enhance the understanding of histaminergic antinociceptive mechanisms, and may lead to the discovery of non-addicting, novel medications for the treatment of pain. ..
  58. HISTAMINERGIC MECHANISMS OF ANALGESIA
    LINDSAY HOUGH; Fiscal Year: 1990
    ..These studies will enhance our knowledge of antinociceptive mechanisms, and may lead to the development of novel, clinically useful agents for the relief of pain...
  59. HISTAMINERGIC MECHANISMS OF ANTINOCICEPTION
    LINDSAY HOUGH; Fiscal Year: 2000
    ....
  60. Gene Expression in Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2006
    ..We present preliminary data on microarray and RT-PCRanalyses on 5 patients with BE that suggest an overactive Wnt pathway: we have also assembled the essential components of a successful study using microarrays. ..
  61. Obesity, H pylori and Risk of Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2009
    ..Subsequently, in a case-control study, all newly diagnosed BE and randomly selected controls will be examined for the volume and activity of visceral obesity (CT scan and serum adipocytokines). ..
  62. Obesity, H pylori and Risk of Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2007
    ..Subsequently, in a case-control study, all newly diagnosed BE and randomly selected controls will be examined for the volume and activity of visceral obesity (CT scan and serum adipocytokines). ..
  63. Clinical Investigation in Pancreatic & Biliary Disorders
    Charles Wilcox; Fiscal Year: 2008
    ..Lastly, an important portion of the mentoring program will be advancing the clinical research of young clinical faculty in their respective research programs. ..
  64. Alzheimer Screening in Primary Care: PRISM-PC Study
    Malaz Boustani; Fiscal Year: 2008
    ..Future directions: We anticipate that participants' responses could guide the design of specific counseling and educational interventions to overcome a patients' reluctance to accept dementia screening. ..
  65. Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
    Hashem El Serag; Fiscal Year: 2009
    ..Evaluating the extent and patterns of HCC surveillance is crucial in understanding diffusion (and obstacles) of this practice and in designing interventions to improve the implementation of HCC surveillance. ..
  66. Gender differences in risks for Barrett's esophagus
    Brian Jacobson; Fiscal Year: 2008
    ..One of the aims of this proposed project addresses the suspected association between obesity and Barrett's esophagus, especially relevant during our nation's current obesity epidemic. ..
  67. Epidemiology and Incidence of Barrett's Esophagus
    Douglas Corley; Fiscal Year: 2008
    ..The proposed study explores how hormones associated with body fat may change the way the body heals after an injury, and increase the risk of cells developing precancerous changes. ..
  68. Alzheimer Screening in Primary Care: PRISM-PC Study
    Malaz Boustani; Fiscal Year: 2007
    ..Future directions: We anticipate that participants' responses could guide the design of specific counseling and educational interventions to overcome a patients' reluctance to accept dementia screening. ..
  69. Mechanisms of Ductus Arteriosus Regulation
    John Reese; Fiscal Year: 2007
    ..These studies will examine new roles for prostaglandins and their relationship with other vasoactive mediators during development. [unreadable] [unreadable]..
  70. Obesity, H pylori and Risk of Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2008
    ..Subsequently, in a case-control study, all newly diagnosed BE and randomly selected controls will be examined for the volume and activity of visceral obesity (CT scan and serum adipocytokines). ..
  71. Risk Factors for Barrett's Esophagus
    Brian C Jacobson; Fiscal Year: 2010
    ..These questions are especially relevant given our nation's current obesity epidemic. ..
  72. Alzheimer Screening in Primary Care: PRISM-PC Study
    Malaz Boustani; Fiscal Year: 2009
    ..Future directions: We anticipate that participants'responses could guide the design of specific counseling and educational interventions to overcome a patients'reluctance to accept dementia screening. ..
  73. Epidemiology and Incidence of Barrett's Esophagus
    Douglas Corley; Fiscal Year: 2009
    ..The proposed study explores how hormones associated with body fat may change the way the body heals after an injury, and increase the risk of cells developing precancerous changes. ..
  74. Medications and the Risk of Sudden Cardiac Death
    Wayne Ray; Fiscal Year: 2006
    ..The study will provide data that clinicians need to prescribe these widely used medications in a way that minimizes the risk of sudden cardiac death. ..
  75. Mechanisms of Ductus Arteriosus Regulation
    JOHN JEFFREY REESE; Fiscal Year: 2010
    ..These studies will examine new roles for prostaglandins and their relationship with other vasoactive mediators during development. ..
  76. Enhancing Care for Hospitalized Older Adults with CI
    Malaz Boustani; Fiscal Year: 2008
    ..abstract_text> ..
  77. Mechanisms of Ductus Arteriosus Regulation
    John Reese; Fiscal Year: 2006
    ..These studies will examine new roles for prostaglandins and their relationship with other vasoactive mediators during development. [unreadable] [unreadable]..
  78. Risk Factors for Barrett's Esophagus
    Brian Jacobson; Fiscal Year: 2007
    ..M. Michael Wolfe, well-established investigators in health-services research. At the completion on the project, the candidate will have gained the experience to become an independent researcher in clinical epidemiology. ..
  79. Medications and the Risk of Sudden Cardiac Death
    Wayne Ray; Fiscal Year: 2007
    ..The study will provide data that clinicians need to prescribe these widely used medications in a way that minimizes the risk of sudden cardiac death. ..
  80. Pharmacological Management of Delirium
    Malaz Boustani; Fiscal Year: 2010
    ..A major advantage of the proposed individualized intervention is reducing exposure to potentially harmful medications and using low dose of haloperidol during the critical early days of ICU care. ..
  81. Mechanisms of Ductus Arteriosus Regulation
    John Reese; Fiscal Year: 2009
    ..These studies will examine new roles for prostaglandins and their relationship with other vasoactive mediators during development. ..
  82. VANDERBILT CENTER FOR EDUCATION/RESEARCH ON THERAPEUTICS
    Wayne Ray; Fiscal Year: 2007
    ..These projects are tightly linked to our theme/sub-theme and have the potential to materially improve clinical practice in highly vulnerable populations that often are under-represented in other research programs. ..
  83. Medications and the Risk of Sudden Cardiac Death
    Wayne Ray; Fiscal Year: 2005
    ..The study will provide data that clinicians need to prescribe these widely used medications in a way that minimizes the risk of sudden cardiac death. ..
  84. Risk Factors for Barrett's Esophagus
    Brian Jacobson; Fiscal Year: 2008
    ..M. Michael Wolfe, well-established investigators in health-services research. At the completion on the project, the candidate will have gained the experience to become an independent researcher in clinical epidemiology. ..
  85. Epidemiology and Incidence of Barrett's Esophagus
    Douglas Corley; Fiscal Year: 2005
    ....
  86. Epidemiology and Outcomes of Digestive and Liver Diseases: A Mentoring Program
    Hashem El Serag; Fiscal Year: 2008
    ..pylori infection on BE tissue COX-2 expression. ..
  87. PROSTAGLANDIN SIGNALING IN FEMALE REPRODUCTION
    John Reese; Fiscal Year: 2005
    ..The results of these experiments will enhance the understanding of maternal-fetal PG signaling, and are likely to provide new insights into premature or dysfunctional labor in women. ..
  88. Epidemiology and Incidence of Barrett's Esophagus
    Douglas Corley; Fiscal Year: 2006
    ....
  89. Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
    Hashem El Serag; Fiscal Year: 2008
    ..Evaluating the extent and patterns of HCC surveillance is crucial in understanding diffusion (and obstacles) of this practice and in designing interventions to improve the implementation of HCC surveillance. ..
  90. Enhancing Care for Hospitalized Older Adults with CI
    Malaz Boustani; Fiscal Year: 2007
    ..abstract_text> ..
  91. Medications and the Risk of Sudden Cardiac Death
    Wayne Ray; Fiscal Year: 2008
    ..The study will provide data that clinicians need to prescribe these widely used medications in a way that minimizes the risk of sudden cardiac death. ..
  92. Low-cost tethered capsule endoscope for screening for Barrett's esophagus
    Jason Dominitz; Fiscal Year: 2008
    ..This has important public health implications since a cost-effective screening tool for BE could help reduce the rising incidence of deaths from esophageal adenocarcinoma. ..